Table of Contents
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 15, 2002
La Jolla Pharmaceutical Company
(Exact Name of Registrant as Specified in Charter)
Delaware | 0-24274 | 33-0361285 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
6455 Nancy Ridge Drive, San Diego, California | 92121 | |||
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (858) 452-6600
N/A
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events | ||||||||
Item 7. Exhibits | ||||||||
SIGNATURE | ||||||||
EXHIBIT INDEX | ||||||||
EXHIBIT 4.1 | ||||||||
EXHIBIT 4.2 | ||||||||
EXHIBIT 99.1 |
Table of Contents
Item 5. Other Events
On January 15, 2002, La Jolla Pharmaceutical Company (the “Company”) announced that it has entered into definitive purchase agreements for the sale of 7,000,000 restricted shares of newly issued common stock to institutional and other accredited investors (the “Purchasers”), for gross proceeds of approximately $51.6 million. The transactions are expected to close on January 18, 2002. The Company has agreed to register the shares of common stock for resale.
A form of stock purchase agreement and form of registration rights agreement between the Company and Purchasers are attached hereto as Exhibit 4.1 and Exhibit 4.2, respectively. The press release announcing the execution of the purchase agreements is attached hereto as Exhibit 99.1.
Item 7. Exhibits
Pursuant to General Instruction F of Form 8-K, the following documents are incorporated by reference herein and attached as exhibits hereto:
Exhibit | Description | |
4.1 | Form of Stock Purchase Agreement between the Company and Purchasers. | |
4.2 | Form of Registration Rights Agreement between the Company and Purchasers. | |
99.1 | Press Release of the Company, dated as of January 15, 2002. |
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned hereunto duly authorized.
La Jolla Pharmaceutical Company | ||||||
Date: January 16, 2002 | By: | /s/ Steven B. Engle | ||||
Steven B. Engle Chief Executive Officer |
Table of Contents
EXHIBIT INDEX
Exhibit | Description | |
4.1 | Form of Stock Purchase Agreement between the Company and Purchasers. | |
4.2 | Form of Registration Rights Agreement between the Company and Purchasers. | |
99.1 | Press Release of the Company, dated as of January 15, 2002. |